Europe Contrast and Imaging Agents in Interventional X-Ray Market, By Agent Type (Iodinated Contrast Media, Barium-Based Contrast Media, Microbubble Contrast Media, Gold Nanoparticle Contrast Agents, Others), Application (Cardiology, Gastroenterology, Neurology, Oncology, Urology, General Surgery), End User (Imaging Centers, Hospital, Clinics, Diagnostic Center, Ambulatory Surgical Centers, Private Practices) – Industry Trends and Forecast to 2030.
Europe Contrast and Imaging Agents in Interventional X-Ray Market Analysis and Size
The rapid increase in the prevalence of stroke and cardiovascular disorder is primary factor responsible for driving the growth of the Europe contrast and imaging agents in interventional X-Ray market. Additionally, the rising demand for minimally invasive procedures, revelation to reduced amount of radiation and high imaging quality and growing demand for minimally invasive diagnostic and surgical procedures as well as the growing prevalence and incidence of chronic diseases also heighten the overall growth of the market. However, the rising adoption of refurbished interventional X-Ray systems are estimated to obstruct the market’s growth.
Data Bridge Market Research analyses that the Europe contrast and imaging agents in interventional X-Ray market which was USD 1.20 billion in 2022, is expected to reach USD 3.46 billion by 2030, and is expected to undergo a CAGR of 5.13% during the forecast period 2023-2030. This indicates that the market value “oncology” dominates the application segment of the Europe contrast and imaging agents in interventional X-Ray market owing to an increase in the number of cancer cases overall the region. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Europe Contrast and Imaging Agents in Interventional X-Ray Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Agent Type (Iodinated Contrast Media, Barium-Based Contrast Media, Microbubble Contrast Media, Gold Nanoparticle Contrast Agents, Others), Application (Cardiology, Gastroenterology, Neurology, Oncology, Urology, General Surgery), End User (Imaging Centers, Hospital, Clinics, Diagnostic Center, Ambulatory Surgical Centers, Private Practices)
|
|
Countries Covered
|
Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe
|
|
Market Players Covered
|
General Electric (U.S.), Bracco (Italy), Ziehm Imaging GmbH (Germany), Lantheus Medical Imaging, Inc. (U.S.), Hitachi Ltd (Japan), Guerbet (France), Siemens (Germany), FUJIFILM VisualSonics Inc (Canada), Jodas Expoim (India), Technix S.p.a. (Italy), Hologic Inc (U.S.), Medtronic (Ireland), TAEJOON PHARM (South Korea0, Unijules Life Sciences Ltd. (India), J.B.Chemicals & Pharmaceuticals Ltd (India), Novalek Pharmaceuticals Pvt. Ltd. (India), Nano Therapeutics Pvt Ltd (India)
|
|
Market Opportunities
|
|
Market Definition
Contrast and imaging agents in interventional X-Ray basically improves the health-related issues. Contrast material, is also referred as contrast agents/media, it improves image quality produced by computed tomography (CT), x-rays and others, which help to distinguish abnormal conditions within the body.
Europe Contrast and Imaging Agents in Interventional X-Ray Market Dynamics
Drivers
- Increasing Prevalence of Chronic Diseases
The rising prevalence of chronic diseases such as cardiovascular diseases, cancer, and neurological disorders in Europe has led to an increased demand for interventional X-Ray procedures. Contrast and imaging agents are crucial in diagnosing and treating these conditions, driving the market's growth.
- Advancements in Imaging Technologies
Continuous advancements in interventional X-Ray technologies, including fluoroscopy, angiography, and computed tomography (CT), have increased the need for high-quality contrast and imaging agents. These agents enhance the visibility and accuracy of imaging, which is essential for effective diagnosis and treatment planning.
- Growing Investment in Research and Development
Both pharmaceutical companies and research institutions are investing significantly in the research and development of imaging technologies. Additionally, increased healthcare investments in research and development have driven innovation in contrast and imaging agents, making them more effective and safer for patients.
- Growing Investment for Healthcare Facilities
Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.
Opportunities
- Rising Demand for Minimally Invasive Procedures
There is a growing trend toward minimally invasive interventional procedures in Europe due to their reduced patient recovery times and shorter hospital stays. This shift presents an opportunity for contrast and imaging agents, as they play a crucial role in enhancing visualization during minimally invasive interventions, such as angioplasty and stent placement.
- Expanding Applications in Oncology
Interventional radiology procedures, including image-guided tumor ablations and selective internal radiation therapy (SIRT), are increasingly used in cancer treatment. The development of specialized contrast and imaging agents tailored for oncology applications offers significant growth potential, as it enables precise tumor targeting and monitoring.
Restraints/ Challenges
- Rising Demand for Minimally Invasive Procedures
There is a growing trend toward minimally invasive interventional procedures in Europe due to their reduced patient recovery times and shorter hospital stays. This shift presents an opportunity for contrast and imaging agents, as they play a crucial role in enhancing visualization during minimally invasive interventions, such as angioplasty and stent placement.
- Expanding Applications in Oncology
Interventional radiology procedures, including image-guided tumor ablations and selective internal radiation therapy (SIRT), are increasingly used in cancer treatment. The development of specialized contrast and imaging agents tailored for oncology applications offers significant growth potential, as it enables precise tumor targeting and monitoring.
- Regulatory Challenges and Safety Concerns
Stringent regulatory requirements and safety concerns surrounding contrast and imaging agents can pose significant restraints. Regulatory changes or safety issues may lead to delays in product approvals or recalls, affecting market access and profitability for manufacturers.
- High Cost of Imaging Agents
Contrast and imaging agents can be expensive, especially when used in large quantities or for complex interventional procedures. The high cost of these agents can limit their adoption, particularly in healthcare systems with budget constraints.
This Europe contrast and imaging agents in interventional X-Ray market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe contrast and imaging agents in interventional X-Ray market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In December 2021, Guerbet and Bracco Imaging announced a Europe collaboration for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent
- In December 2021, Qaelum NV announced a strategic partnership with Ulrich GmbH & Co. KG in Ulm to combine their advanced Contrast Management solution with the contrast media injectors of Ulrich Medical to support the needs of hospitals and imaging networks
Europe Contrast and Imaging Agents in Interventional X-Ray Market Scope
The Europe contrast and imaging agents in interventional X-Ray market is segmented on the basis of agent type, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Agent Type
- Iodinated Contrast Media
- Barium-Based Contrast Media
- Microbubble Contrast Media
- Gold Nanoparticle contrast agents
- Others
Application
- Cardiology
- Gastroenterology
- Neurology
- Oncology
- Urology
- General surgery
End User
- Imaging centers
- Hospital
- Clinics
- Diagnostic center
- Ambulatory surgical centers
- Private practices
Europe Contrast and Imaging Agents in Interventional X-Ray Market Regional Analysis/Insights
The Europe contrast and imaging agents in interventional X-Ray market is analysed and market size insights and trends are provided by country, agent type, application and end user as referenced above.
The countries covered in the Europe contrast and imaging agents in interventional X-Ray market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
Germany dominates the Europe contrast and imaging agents in interventional X-Ray market because of the rise in the prevalence of chronic diseases within the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The Europe contrast and imaging agents in interventional X-Ray market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Europe contrast and imaging agents in interventional X-Ray market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Europe contrast and imaging agents in interventional X-Ray market. The data is available for historic period 2015-2020.
Competitive Landscape and Europe Contrast and Imaging Agents in Interventional X-Ray Market Share Analysis
The Europe contrast and imaging agents in interventional X-Ray market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Europe contrast and imaging agents in interventional X-Ray market.
Some of the major players operating in the Europe contrast and imaging agents in interventional X-Ray market are:
- General Electric (U.S.)
- Bracco (Italy)
- Ziehm Imaging GmbH (Germany)
- Lantheus Medical Imaging, Inc. (U.S.)
- Hitachi Ltd (Japan)
- Guerbet (France)
- Siemens (Germany)
- FUJIFILM VisualSonics Inc (Canada)
- Jodas Expoim (India)
- Technix S.p.a. (Italy)
- Hologic Inc (U.S.)
- Medtronic (Ireland)
- TAEJOON PHARM (South Korea)
- Unijules Life Sciences Ltd. (India)
- J.B.Chemicals & Pharmaceuticals Ltd (India)
- Novalek Pharmaceuticals Pvt. Ltd. (India)
- Nano Therapeutics Pvt Ltd (India)
SKU-